Decreased Systemic Levels of Endocan-1 and CXCL16 in Psoriasis Are Restored following Narrowband UVB Treatment

Dermatology. 2018;234(5-6):173-179. doi: 10.1159/000491819. Epub 2018 Sep 3.


Background: In psoriasis, a common immune-mediated disease affecting 2-3% of the population worldwide, there is an increased prevalence of extracutaneous diseases including obesity, the metabolic syndrome, and cardiovascular disease. This is believed to be linked to systemic inflammation. In previous studies, we have explored various markers in plasma and serum to characterize the ongoing systemic inflammation in psoriasis patients compared to controls. We have identified several markers that were altered in psoriasis patients, but which all were unresponsive to narrowband UVB (NB-UVB) treatment.

Objective: The objective of the study was to evaluate the effect of NB-UVB treatment on markers of cardiovascular risk and systemic inflammation in psoriasis.

Methods: The levels of 17 potential biomarkers with an association with cardiovascular risk were quantitated in plasma from 37 age- and gender-matched psoriasis patients and controls at baseline and in 21 psoriasis patients after 12 weeks of NB-UVB treatment to identify a systemic treatment response.

Results: We identified the mediators endocan-1, CXCL16, and sVEGFR1, which were systemically decreased in psoriasis at baseline, as well as FABP3, FABP4, and sIL-1R1, which showed normal baseline levels. After 10-12 weeks of NB-UVB treatment, endocan-1 and CXCL16 were restored to normal levels, while sVEGFR1, FABP3, FABP4, and sIL-1R1 showed a significant reduction.

Conclusion: The current study expands the number of potential biomarkers in psoriasis by including a greater number and variety of mediators, approaching the systemic inflammation from additional vantage points, including soluble immune receptors and adipocyte contribution, to provide a more complete picture of the systemic inflammatory state in psoriasis.

Keywords: Cardiovascular risk; Psoriasis; Skin; UVB.

MeSH terms

  • Biomarkers / blood
  • Cardiovascular Diseases / blood
  • Case-Control Studies
  • Chemokine CXCL16 / blood*
  • Fatty Acid Binding Protein 3 / blood
  • Fatty Acid-Binding Proteins / blood
  • Humans
  • Neoplasm Proteins / blood*
  • Proteoglycans / blood*
  • Psoriasis / blood*
  • Psoriasis / radiotherapy*
  • Receptors, Interleukin-1 Type I / blood
  • Ultraviolet Therapy* / methods
  • Vascular Endothelial Growth Factor Receptor-1 / blood


  • Biomarkers
  • CXCL16 protein, human
  • Chemokine CXCL16
  • ESM1 protein, human
  • FABP3 protein, human
  • FABP4 protein, human
  • Fatty Acid Binding Protein 3
  • Fatty Acid-Binding Proteins
  • IL1R1 protein, human
  • Neoplasm Proteins
  • Proteoglycans
  • Receptors, Interleukin-1 Type I
  • Vascular Endothelial Growth Factor Receptor-1